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Abstract
Background: Acute Coronary Syndromes account for 15% of deaths in the UK, and patients
remain at significant risk of re-admission for future complications and death. Pathologically the
underlying process of atherosclerosis is driven by inflammatory mechanisms, which are activated in
ACS patients. Previous studies have investigated the role of inflammatory markers in this process,
including interleukin 1 (IL-1) and C Reactive Protein (CRP). Pre-clinical studies indicate that IL-1
may be a primary driver of ACS and that the naturally occurring interleukin-1 receptor antagonist
(IL-1ra) may inhibit the atherosclerotic process. This study will investigate the effects of IL-1ra on
inflammatory markers in man.
Methods/design: Three centres in the UK are planning to recruit 186 Non-ST elevation
myocardial infarction patients to receive either interleukin-1 receptor antagonist (Anakinra) or
matching placebo. Patients will receive a daily subcutaneous injection of either study drug or
placebo over a 14 day period. The primary outcome is area under the curve of high sensitivity C-
Reactive Protein (CRP) over the first 7 days.
Discussion: The MRC-ILA-HEART Study is a proof of concept clinical trial investigating the effects
of IL-1ra upon markers of inflammation in patients with Non-ST elevation myocardial infarction. It
is hoped this will provide new and exciting information in relation to an "anti-inflammatory"
strategy for patients with acute coronary syndrome.
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Acute coronary syndromes (ACS), caused by coronary
atherosclerotic plaque destabilisation and interruption of
coronary flow, are common, serious conditions that
account for 15% of all deaths in the UK and are associated
with considerable morbidity among survivors. ACS are
classified by the presenting ECG: patients with persistent
ST elevation myocardial infarction (STEMI) generally
require early reperfusion [1], whereas those with non ST-
elevation (NSTEMI) ACS require early risk stratification
and revascularisation as necessary [2]. There remains,
however, considerable risk in the non-ST elevation ACS
patients: the average risk of death at 6 months is 6.2%
with 19.3% re-attending hospital because of heart disease
[3]. It is known that inflammatory processes are activated
in ACS. This proposal is for a proof of concept clinical trial
of a new and exciting anti-inflammatory strategy for the
treatment of NSTEMI ACS based on pre-clinical investiga-
tions that we wish to translate to man.
Inflammation and atherosclerosis
The past decade has seen a growth in treatment options
available for ACS as a consequence of better understand-
ing of the pathophysiology of this condition. At a biolog-
ical level the process is driven by inflammatory
mechanisms in the vessel wall where atherogenesis is ini-
tiated by lipids and other environmental agents [4,5].
Instability of the plaque atheroma so as to cause the dis-
ease to present is also viewed as an inflammatory process,
predominantly where plaque macrophages destabilise the
cap of the atheroma, resulting in the formation of an
intra-coronary thrombus.
The therapeutic implications of these pathogenic path-
ways are that primary and, to some extent, secondary pre-
vention are targeted at mutable risk factors (smoking
cessation, blood pressure control, lipid lowering etc.) and
anti-thrombotic strategies for the treatment and preven-
tion of intracoronary thrombus. Evaluation of therapeutic
strategies designed to treat the inflammatory processes
involved in acute or chronic coronary artery disease
(CAD) is at an early stage. Some agents may potentially
have anti-inflammatory properties (statins in particular
and fish oils) but this is not their primary mechanism of
action and proving beneficial effects consequent upon the
anti-inflammatory properties of these agents has been dif-
ficult.
Since the description of ACS as an inflammatory event
potential sources of, and functions for, inflammatory
cytokines in this process have been investigated [5,6]. IL-
1 is an apical cytokine in the innate inflammatory
response transducing signals from bacterial products
through pattern recognition receptors, complement acti-
vation and TNFα. IL-1 has plausible actions in arterial
wall inflammation in the setting of atherosclerosis, in par-
ticular its effects on endothelial cells (activation) and vas-
cular smooth muscle cells (proliferation). There are two
agonistic cytokines (IL-1α and IL-1β) that signal via the
Type 1 IL-1 receptor and there is a specific Interleukin-1
receptor antagonist (IL-1ra), the only known naturally
occurring cytokine antagonist, that inhibits IL-1 actions
by binding to the Type 1 IL-1 Receptor (IL-1RI), blocking
the receptor and preventing IL-1 from binding thereby
preventing receptor signalling [7].
Relevance of interleukin-1
The suggestion that IL-1 is involved in the pathogenesis of
CAD, and in particular in ACS, is derived from a number
of sources as there is no animal model of this condition.
IL-1 and IL-1ra are expressed in diseased human coronary
arteries [8,9]. Coronary artery IL-1β is up-regulated in por-
cine coronary arteries after balloon injury [10]. Genetic
studies have indicated that polymorphic variants within
the IL-1 cluster that have net pro-inflammatory effects are
associated with angiographic CAD [11,12].
In mouse models of atherosclerosis IL-1ra inhibits the for-
mation of intimal fatty streaks in apolipoprotein E-defi-
cient mice [13], and IL-1β deficient mice when crossed
onto an apo e-/- background have reduced atherosclerosis
[14]. Relevant to vessel wall healing, we have data from
mice and pigs that indicate the vessel wall response to
injury (neointima formation) is an intensely IL-1 depend-
ent event [15]. In the porcine coronary artery, the
neointima response to balloon angioplasty (a model of
arterial wall rupture in some way analogous to that which
occurs in ACS) is reduced in its amount by a 14 day s.c.
infusion of IL-1ra. We have crossed the IL-1R1-/- mouse
with the apo e-/- and found reduced atherosclerosis. This
double knockout, unable to signal IL-1, has no rise in
blood pressure with fat feeding (in contrast to the apo e-/
- control mice) and this is associated with reduced serum
amyloid A levels (mice do not appear to have CRP),
reduced markers of oxidative stress in the arterial wall and
preservation of endothelial cell function in resistance
arteries. We have reproduced the blood pressure rise inhi-
bition and the modulation of oxidative stress seen in the
IL-1R1-/-, apo e-/- double knockout by using s.c. IL-1ra
treatment in apo e-/- mice.
In a cohort of 63 NSTEMI ACS patients we examined the
impact of IL-1 gene polymorphisms upon markers of
endothelial cell activation and CRP [16]. The intron 2,
VNTR polymorphism that we have previously described
as associated with reduced endothelial cell production of
IL-1ra [17] (i.e. endothelial pro-inflammatory) was asso-
ciated with significant increases in soluble markers of
endothelial activation at the time of NSTEMI ACS, includ-Page 2 of 14
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ated with clinical outcome [18].
Overall, our preliminary data indicate that 1) IL-1 is a
potent mediator of arterial inflammation in the context of
atherosclerosis and vessel wall injury and 2) IL-1 inhibi-
tion restores endothelial function, reduces inflammatory
vessel wall responses and reduces vascular oxidative stress.
We wish now to translate these findings to man.
Markers of inflammation in ACS
ACS, as has been stated before, is an intensely inflamma-
tory event at the level of the vessel wall. Data from angios-
copy [19], angiography [20], IVUS [21] as well as
functional cell biology [22] indicate that ACS is frequently
associated with widespread coronary activation and
inflammation, indicating a pancoronary inflammatory
state. It has also become clear that serum markers of
inflammation are predictors of complications following
an episode of ACS and that statin therapy associated with
lower achieved levels of CRP are associated with improve-
ment in outcome [23]. These data suggest that modula-
tion of inflammation in the coronary artery would be
predicted to translate to clinical benefit. There is consider-
able interest in markers of outcome in ACS. These broadly
fall into two groups; those that measure the size of the inf-
arct and those that are measures of the pathogenic process
in the vessel way and may reflect both the magnitude and
duration of the process. In the former group are the mark-
ers of myocyte damage. Cardiac-specific Troponin is now
recognised as a more sensitive and specific marker of myo-
cardial necrosis than creatine kinase and its MB isoen-
zyme. Elevation of serum Troponin has been shown to
identify patients with ACS at risk for adverse clinical out-
comes [24-26].
In the latter group (markers of the pathological process)
are the markers of inflammation, coagulation and of
platelet activation. We believe that there are plausible
links between IL-1 activation and these markers. The acute
phase reactant C-reactive protein (CRP) is a strong predic-
tor of cardiovascular events [27,28]. In NSTEMI ACS,
treated with percutaneous coronary intervention (PCI),
CRP rises and peaks between 24 and 48 hours [29]. It is
clear, however, that in some patients there is persistent
elevation with maybe 49% of patients having a CRP >3
mg/L at discharge and these patients were identified as
having increased chances of recurrent admissions [30].
The absolute levels of CRP have been shown to have a
high sensitivity (87%) and a low specificity (54%) for
subsequent myocardial infarction in patients presenting
with an ACS [31]. There is a difficulty using a percentage
change in CRP, either for individual patients and predict-
ing outcome or between two groups of (treated) patients,
in that there is no baseline level from which comparisons
can be made. Differences in outcomes in the PROVE-IT
trial, however, were associated with differences in the
achieved CRP level [23,32]. Biologically, CRP production
by hepatocytes has to be induced and this has been shown
to be driven by the IL-1 and IL-6 cytokines. Serum levels
of IL-6 have been shown to be elevated in patients with
ACS [33] and an elevation of IL-6 is an independent
marker of increased mortality in ACS [30]. The relation-
ship between IL-1 and IL-6 is well defined with IL-1 induc-
ing IL-6 production [7]. It has, however, proved difficult
to reliably measure IL-1β; a cytokine that is devoid of a
signal sequence directing release and which probably cir-
culates at a very low level.
During NSTEMI, a rise in von Willebrand Factor (vWF)
between 24 and 48 h predicts adverse clinical events [18],
and an association between circulating levels of IL-6 and
von Willebrand factor (vWF) has recently been shown to
determine prognosis in patients with ACS [34]. IL-1 has
been shown to augment thrombin-induced release of vWF
from human endothelial cells [35].
Interleukin 1 receptor antagonist (IL-1ra)
There are two agonistic cytokines (IL-1α and IL-1β) that
signal via the Type 1 IL-1 receptor (IL-1R1) and a specific
Interleukin-1 receptor antagonist (IL-1ra), (the only
known naturally occurring cytokine antagonist) that
inhibits IL-1 actions by binding to the IL-1R1, blocking
the receptor and preventing IL-1 from binding thereby
preventing receptor signalling [7].
IL-1ra is available for the treatment of a number of inflam-
matory conditions as a recombinant, non-glycosylated, N-
terminal methionine added protein (Kineret/Anakinra,
Amgen). Although less successful than anti-TNF therapies
in rheumatoid arthritis (RA), there appears to be consid-
erable benefit in the management of Juvenile arthritis
(Still's disease), and it is the treatment of choice in the rare
autoinflammatory illnesses typified by Muckle-Wells syn-
drome. From all of the indications in which IL-1ra has
been used it has emerged that IL-1ra is a very safe form of
treatment and appears to be devoid of the side-effect of re-
activation of infectious illness seen with anti-TNF thera-
pies. The only problems encountered are mild, reversible
injection site reactions and neutropaenia in <1% of
patients after a month or more of treatment.
Dosing with IL-1ra is simple. A single, daily, subcutaneous
100 mg injection of IL-1ra is the standard dose of IL-1ra
for all individuals with normal renal function. In RA this
causes a 35% reduction in CRP after approximately 1
week of treatment. Higher doses do not achieve any
greater reduction in CRP of relief of RA symptoms. Single
daily dosing schedules are used in the sucessful treatment
of Juvenile arthritis and Muckle-Wells. The half-life of IL-Page 3 of 14
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injection at 3–7 hours. (Data on file supplied by Amgen).
Conclusion
All of these data indicate that the IL-1 cytokine has the
potential to act as a primary driver of ACS. Prolonged cor-
onary activation is associated with worse outcome in ACS.
It is therefore plausible that blockade of the IL-1 system
could be of therapeutic benefit. We believe our pre-clini-
cal data indicates that a purely anti-inflammatory
approach based upon Interleukin-1 (IL-1) inhibition
using IL-1 receptor antagonist (IL-1ra) is a feasible and
logical therapy for ACS and this approach could open a
new therapeutic paradigm for evaluation in further stud-
ies.
Aim of study
The main objective is to assess whether treatment of
NSTEMI ACS with IL-1ra alters the inflammatory process
involved in this condition
Trial design
Randomised, double blind, placebo-controlled multi-
centre phase II clinical trial
Eligibility
Inclusion criteria
1. Acute cardiac chest pain consistent with an acute coro-
nary syndrome
2. <48 hours from onset of symptoms that led to hospital
admission
3. And at least one of the following:
a) A raised troponin as defined by local parameters speci-
fied at each centre
b) Other ECG changes consistent with acute myocardial
ischaemia (e.g. Horizontal or down-sloping ST depression
of at least 0.5 mm or T-wave inversion of at least 3 mm, in
at least two leads of the ECG, or new onset bundle branch
block) and an elevated level of Troponin above local lab-
oratory values indicating myocardial damage
Exclusion criteria
1. < 18 years of age
2. Persistent ST elevation on the presenting ECG
3. Intention to treat with an urgent reperfusion strategy
(thrombolysis or primary percutaneous coronary inter-
vention)Percutaneous coronary intervention within pre-
vious 3 months
4. Previous coronary artery bypass grafting
5. ECG showing paced rhythm
6. Cardiogenic shock (as defined in the Trial Manual)
7. Any serious co-morbidity which makes it unlikely that
the patient will complete trial procedures and follow-up
8. Treatment or under active follow-up for rheumatoid
arthritis, other connective tissue diseases or inflammatory
bowel disease
9. End stage renal disease or a Creatinine > 220 μmol/L
10. Pregnancy or suspected pregnancy (any potential
female participant of child bearing age will need a nega-
tive pregnancy test prior to study entry)
11. Eosinophilia
12. Anti-TNF biologies
13. Active infection
14. Malignancy
Study treatment
Eligible patients will be randomised in equal proportions
between IL-1ra and placebo, receiving either a once daily,
subcutaneous (s.c). injection of IL-1ra (dose 100 mg per
24 h) for 14 days, or a daily s.c. injection of placebo for 14
days. The hospital pharmacist will issue the relevant drug
package. (Please see appendices for pharmacy informa-
tion).
The study drug and placebo will be provided by Amgen
Inc in its commercially available recombinant form which
is in clinical use for the treatment of arthritic conditions.
The study drug and placebo will be relabelled by Amgen,
in collaboration with CTEU according to MHRA guide-
lines.
The first dose of IL-1ra will be given within 24 h +2 h of
the positive Troponin. Injections will be given at a stand-
ardised time (24 ± 2 h after the previous dose), immedi-
ately after blood sampling. IL-1ra or placebo will
administered to the patient by the research nurse while
the patient is in hospital. During the hospital stay, the
patient will be taught to self-administer the injection by
the research nurse and on discharge will continue at
home. This has proven possible in other ACS trials that
required self injection of subcutaneous heparin [36]. Full
written guidance on self injection will also be provided to
patients. If self injection is found not to be possible in anPage 4 of 14
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method will be sought (e.g. district nurse, or attending the
hospital) to try and maintain full compliance with sched-
uled study drug regimen after discharge. Patients will also
be asked to complete a daily injection diary. All personnel
will be blinded to the identity of the syringe contents.
Concomitant treatments and procedures
All patients will receive standardised additional treat-
ments according to best practice including aspirin, clopi-
dogrel, heparin (intravenous or low-molecular weight), a
glycoprotein IIb/IIIa inhibitor and a statin. Other medica-
tion will be at the physicians' discretion. It is the intention
that all patients will proceed to coronary angiography
according to current guidelines, and subsequent revascu-
larisation if necessary.
Drug composition
Each vial contains 100 mg of anakinra in 1 ml (100 mg/
ml). Anakinra is a human interleukin – 1 receptor antag-
onist (r -metHuIL -1ra) produced by recombinant DNA
technology in an E coli expression system.
Marketing authorisation Holder
Amgen Europe B.V., Minervum 7061, 4817 ZK Breda, The
Netherlands
Placebo composition
Each vial consists of sodium citrate, sodium chloride, dis-
odium edentate, polysorbate 80, sodium hydroxide and
water for injection.
Screening and enrolment
Participating centres and investigators have extensive
experience of clinical trials and admit large numbers of
patients with acute coronary syndromes. It is expected
that screening for eligible patients will occur on a daily
basis and potentially eligible patients will be approached
for consent to participate. Screening for patients should
occur routinely in ward areas that admit ACS patients.
Centres are encouraged to screen and enrol at the week-
ends and out of hours depending on local resources. Each
centre is requested to randomise and follow-up an average
of 62 patients (30 per annum or 2–3 patients per month)
over a 2 year period.
Screening procedure
A member of the research team will screen patients for eli-
gibility as soon as possible after presentation. If patients
meet the eligibility criteria they will be given the patient
information sheet to consider. Patients will be given as
much time as they require to consider taking part but due
to the acute nature of this condition, patients will be
recruited as soon as possible after the positive troponin is
confirmed. A TIMI (Thrombolysis in Myocardial Infarc-
tion) and GRACE risk score will be determined for each
patient at baseline [1,37].
Informed consent
"Informed consent" requires individual discussion with
the patient about the nature of the procedures to be con-
ducted in a language that is easy to comprehend. The
patient should fully understand that he/she might be allo-
cated to either the IL-1ra or the placebo group and the
potential adverse effects of participation. The patient
should also understand that his/her refusal to participate
in the study will not affect the quality of subsequent med-
ical care and if they do consent to participate they may
withdraw at any point without affecting their care.
Before any trial-related procedures may be performed,
informed consent must be obtained from the patient by
the investigator by means of a signed declaration. The
investigator must sign in the CRF to confirm that
informed consent was obtained and store the original of
the signed declaration of consent in the patient's notes. A
copy should be given to the patient and a copy filed in the
CRF.
Randomisation
Randomisation will be performed using a 24-hour voice
interactive system set up the trial co-ordinating centre
(Clinical Trials and Evaluation Unit (CTEU) of the Royal
Brompton Hospital, London). Centres will be asked for a
few simple details about the patient including initials,
date of birth and eligibility criteria. The caller will be given
a randomisation number, corresponding to blinded study
treatment, and a fax or e mail will be sent to the centre
confirming this. Randomisation will be stratified by cen-
tre and by whether glycoprotein IIb/IIIa antagonists are
being used or planned. Patients entered into the study in
this way will be considered as part of the intention to treat
cohort irrespective of whether they actually receive treat-
ment or not, or if they subsequently with draw from the
study.
Study related investigations and follow-up
Patients will have blood taken every day for seven days for
hsCRP (baseline and days 1–7, 14 and 30), Troponin
(baseline and days 1–7 and 14), full blood count (base-
line, days 7 and 14), creatinine, electrolytes, liver function
tests (baseline, days 1–7 and 14), Interleukin-6 and von
Willebrand factor (baseline, days 1–3,14,30). Blood will
be taken prior to administration of either IL-1ra or pla-
cebo. A summary of samples and study related procedures
to be undertaken is shown in Table 1. If the patient is dis-
charged before the seventh day, they will be required to
attend clinic to have the remaining blood samples taken.Page 5 of 14
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All patients will be followed up for MACE at 30 days (at
clinic), three months and one year by telephone call with
the Research Nurse. Patients will also be followed up for
up to five years by the ONS.
Collection of blood for DNA/RNA
Common genetic variations in the IL-1β gene have been
shown to influence IL-1 β production and been impli-
cated in the causation of premature coronary artery dis-
ease. IL-1β effects are mediated via the IL-1 receptor that is
antagonised by IL-1ra. As with other receptors, stimula-
tion may result in down-regulation and inhibition in up-
regulation. We aim to demonstrate this by measurement
of IL-1r mRNA expression. Genomic DNA and mRNA
samples will be collected, stored and studied. These will
be used to study the genetic substrate of observed differ-
ences in inflammatory markers and also effects of IL-1ra
treatment – with initial experimental questions being as
outlined here. Two additional blood samples will be
taken at base-line and follow up at day 30 (1) 6 ml blood
in EDTA tube for DNA extraction using the 'Versagene'
DNA purification system (2) 5 ml blood in 'PAXgene' vac-
uum tube.
Sub-studies
There are three sub studies proposed for the study (please
see appendix 1.2. for protocols) including:
1. Cardiac Magnetic Resonance (CMR) – Leeds Patients
only
2. ST-Holter segment analysis – Sheffield patients only
3. Forearm Endothelial Cell response – Edinburgh
patients only
Outcome measures
Primary outcome measure (comparison of treatment group with 
control)
Area under the curve of serum high sensitivity CRP over
the first 7 days
Secondary outcome measures (comparison between treatment and 
control of)
1. Mean hsCRP at 7, 14 and 30 days
2. Area under the curve of Troponin-I
3. vWF and IL-6
4. ST segment depression on Holter monitor
5. Myocardial injury as determined by Gadolinium
enhanced CMR scan
6. Forearm endothelial cell response
7. Incidence of major adverse cardiovascular events
(MACE) at 30-days, three months and at one year.
8. Flagging with Office of National Statistics (ONS) for up
to 5 years.
Statistics
Sample size
To provide the study with an 80% power to detect a rela-
tive reduction of one-third (the reduction seen in IL-1ra
treatment of rheumatoid arthritis at this dose (data on file
[Amgen]) between the treatment and the placebo groups
at a 5% level of significance will require approximately 80
patients in each group (total 160). This is based upon the
log-transformed value of the area under the curve and a
Table 1: Study procedures
Procedure Baseline Days 1 – 7 Days 8–13 Day 14 Day 30 (end of study)
Clinical evaluation √ √ √ √
Informed consent √
Randomisation √
ECG √ √ √
Study drug given √ √ √
Full blood count √ √ √
Creatinine, electrolytes, eGFR √ √ √
Troponin √ √ √
hsCRP √ √ √ √
Liver function tests √ √
IL-6, vWF √ √ √ √
Post discharge follow up visit √ √
Samples for DNA & RNA √ √
Cardiac magnetic resonance scan (1) √ √
ST segment monitoring (2) √
Forearm endothelial study (3) √ √Page 6 of 14
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[D]) of approximately 0.45. The standardised difference
had been used since it is very difficult to estimate what the
values of the log-transformed AUC will be. A change of
0.45 on the standardised normal will correspond to a one-
third change in the primary outcome, regardless of the
scale of the measurement, assuming the outcome measure
is normally distributed. As the sample size is sufficiently
powered to detect a change equivalent to one-third on the
standard normal, it will also be sufficient to detect the
same level of change on the primary outcome measure. It
is anticipated that follow-up will be near complete in this
study. However, allowing for data loss, for whatever rea-
son, of 10% in each arm we have increased the required
sample size to approximately 180 patients (60/centre).
Furthermore, the sample size needs to be adjusted for the
2 interim analyses that will be conducted during the trial.
Using the method of O'Brien and Flemming (1979) gives
an increased sample size of 184 patients.).
Interim analyses
A limited number of interim analyses will be performed
by the trial statistician as specified by the Data Monitoring
Committee (DMC). The accumulating results will not be
available to the trialists or other principal investigators.
The final, definitive analysis of the trial data will be con-
ducted 25 months after the date of commencement of the
trial. The interim analysis will test for efficacy, safety and
futility. The method of O'Brien and Fleming suggests that
stopping for efficacy will only occur if the first interim
analysis shows a treatment effect equivalent to p < 0.0005
or if the second interim analysis shows a treatment effect
equivalent to p < 0.014.
Primary analysis
Primary analysis will be of log-transformed AUC of 7 day
CRP. The primary analysis will include all patients with at
least 4 follow-up readings, on an intention-to-treat basis,
and a secondary analysis will include only those with all
follow-up readings on a per-protocol basis. ANOVA (anal-
ysis of variance) will be used to analyse the primary out-
come measure and to estimate the treatment effect. For
patients with at least 4 readings, any missing measure-
ments will be imputed using the last observation carried
forward method. After adjustment for the interim analy-
ses, based on the method of O'Brien and Fleming, the pri-
mary endpoint will be considered to be statistically
significant if it shows a treatment effect equivalent to p <
0.045.
Trial organisation and committees
Trial steering committee (TSC)
The main role of the TSC is to monitor and supervise the
progress of the trial. The TSC membership is listed in
Table 2.
Representatives from the sponsor organisation, University
of Sheffield, and funding organisation, Medical Research
Council, will attend the Trial Steering Committee as
observers.
Data monitoring committee (DMC)
The main role of the DMC is to consider the data from any
interim analyses and specifically to assess any safety issues
(such as unexpected serious adverse events) that occur
and report back to the TSC. The DMC membership is
listed in Table 3. All members of the DMC are independ-
ent of the trial. The DMC will meet prior to the start of the
trial and then one and two thirds of the way through the
Trial or as required thereafter. The DMC will be expected
to develop, in agreement with the investigators, a charter
outlining their responsibilities and operational details.
Clinical event review committee
The Clinical Event Review Committee will review adverse
events during the study and adjudicate them to ensure the
events meet the definitions given. Each event will be inde-
pendently adjudicated by two committee members. A
Table 2: Trial steering committee membership
Name Trial Role Title Affiliation
Professor D Crossman Chief Investigator Professor of Cardiology Sheffield
Dr Philippa Tyrrell Independent Chair Senior Lecturer in Stroke Manchester
Dr Mark DeBelder Independent Cardiologist Consultant Cardiologist South Tees
Dr A Morton Co-investigator Clinical Lecturer in Cardiology Sheffield
Professor A Hall Co-investigator Professor of Cardiology Leeds
Professor K Fox Co-investigator Professor of Cardiology Edinburgh
Mr Michael Roughton Study Statistician Statistician, Royal Brompton Hospital London
Dr M Flather Co-investigator Director, CTEU, Royal Brompton Hospital London
Dr J Greenwood Co-investigator Senior Lecturer in Cardiology Leeds
Dr J Gunn Co-investigator Senior Lecturer in Cardiology Sheffield
Mrs Bev Kilner Recruiting Nurse Research Sister Sheffield
Mr Graham Seaton Lay memberPage 7 of 14
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event if agreement is not reached by two members. The
adjudications will be blind to the knowledge of which
arm of the trial the patients are in.
Study co-ordination
The study will be co-ordinated and managed by the Clin-
ical Trials and Evaluation Unit (CTEU) a dedicated clini-
cal trials department within the Royal Brompton
Hospital. In addition to providing overall project co-ordi-
nation, the CTEU will assist in preparing the final proto-
col, the investigators' manuals, design the Case Report
Forms (CRF), provide the randomisation service and
design and instigate the data management system. The
CTEU will ensure that the trial runs according to the pre-
agreed timetable, recruitment targets are met, CRFs are
completed accurately, compliance with relevant ethical
and regulatory standards, and that all aspects of the study
are performed to the highest quality. The CTEU will also
assist in the training of investigators and co-ordinators at
the start-up of the study and for performing monitoring
procedures throughout. A smaller trial management team
consisting of lead investigators at each site and CTEU will
meet weekly by conference call.
Regulatory issues
Study sites
Support for patient identification, study administration,
data collection and follow-up will be provided to each
participating site. Study site co-ordinators will be respon-
sible for screening patients (and recording the data on a
screening log), enrolling patients into the trial, providing
a contact point for patients, liaising with CTEU, complet-
ing CRFs, arranging all follow up visits and measure-
ments, recording adverse events, ensuring forms are sent
to CTEU and that all edit queries are resolved.
Data collection
Each centre will be provided with a Protocol, Manual of
Operations, questionnaires and patient CRFs. Data will be
recorded onto two part NCR CRFs and the top copy sent
to the CTEU at the times specified.
Investigators' responsibilities
Investigators must ensure that Local Ethics Committee
approval has been obtained as well as Agreements signed
off by their Institution prior to the start of the study. Inves-
tigators are responsible for performing the study in
accordance with the European Clinical Trials Directive,
the Medicines for Human Use (Clinical Trials) Regula-
tions 2004, NHS Research Governance, MRC Guidelines
for Good Clinical Practice in Clinical Trials (1998) and
the Declaration of Helsinki guidelines. Investigators are
required to ensure compliance to the protocol, CRFs and
Manual of Operations. Investigators are required to allow
access to study documentation or source data on request
for monitoring visits and audits performed by the CTEU
or any regulatory authorities.
Pre-study training visit
Before the study commences each centre will receive a
training visit by CTEU. These visits will ensure that per-
sonnel at each site (including principal investigators, co-
investigators, study site co-ordinator and pharmacists)
fully understand the protocol, CRF and the practical pro-
cedures for the study.
Monitoring visits
At regular intervals during the study CTEU will perform
monitoring visits to each centre. The purpose of these vis-
its is to ensure compliance to the protocol and that ethical
and regulatory guidelines are met. Source data verification
and checking of essential documents will be performed.
Monitoring visits also provide an opportunity for further
training if required (eg new staff). Central review of study
data will also be performed throughout the study.
Close out visit
At the end of the study each centre will receive a site visit
from CTEU to resolve any outstanding edit queries or
adverse events and to verify the correct storage of study
documentation.
Regulatory framework and approval
This study is a randomised trial of a medicinal product in
a new indication. The IL1-receptor antagonist is commer-
cially available and approved for use in specific inflamma-
tory conditions. As such the study will need to comply
with the European Clinical Trials Directive and the Medi-
cines for Human Use (Clinical Trials) Regulations 2004.
An application will be made for a clinical trials authorisa-
tion (CTA) to the Medicines and Healthcare Regulatory
Table 3: Data monitoring committee membership
Name Trial Role Title Affiliation
Professor R Willcox Chair Professor of Cardiology Nottingham
Dr Allan Skene Statistician Managing Director of Nottingham Clinical Research Group Nottingham
Dr E Grech Cardiology advisor Consultant Cardiologist SheffieldPage 8 of 14
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been registered in the European Community with a
Eudract number.
Study sponsor
The grant has been awarded to the University of Sheffield
who will act as the main Sponsor of the study. The Spon-
sor's role is clearly set out in the European Clinical Trials
Directive and NHS Research Governance documents.
Research agreements will be held with the 4 collaborating
groups: University of Edinburgh/Royal Infirmary of Edin-
burgh, University Hospitals of Leeds, Sheffield Hospitals
NHS Trust and Royal Brompton and Harefield NHS Trust.
The Clinical Trials and Evaluation Unit of the Royal
Brompton will be responsible, on behalf of the University
of Sheffield, for ensuring that regulatory compliance is
carried according to the high standards expected.
Safety reporting
The University of Sheffield (Sponsor) has delegated
responsibility for pharmacovigilance to the trial co-ordi-
nating centre (Clinical Trials and Evaluation Unit (CTEU)
of the Royal Brompton Hospital, London).
The CTEU will be responsible for recording all reported
serious adverse events from investigational trial sites,
reporting all serious adverse events to a constituted seri-
ous adverse events committee (SAEC) for review and
expedited reporting of suspected unexpected serious
adverse reactions (SUSARs) in accordance with statutory
regulations. The SAEC will consist of one nominated
investigator from each trial site who can provide clinical
expertise to adjudicate serious adverse events and deter-
mine if they are SUSARs, and advise the CTEU whether
expedited reporting is required.
Adverse reactions (AR)
An adverse reaction of an investigational medicinal prod-
uct (AR) can be defined as all untoward and unintended
responses to an investigational medicinal product related
to any dose administered.
In the event an AR is reported during the trial, investiga-
tors will assess the severity of the adverse event using the
following criteria, detailed on the adverse event report
form in the case report form (CRF):
Mild: Awareness of signs or symptoms, but easily toler-
ated; are of minor irritant type; causing no loss of time
from normal activities; symptoms would not require med-
ication.
Moderate: Discomfort severe enough to cause interference
with usual activities.
Severe: Inability to do work or usual activities; signs and
symptoms may be of systemic nature or require medical
evaluation and/or treatment.
Drug related adverse reactions
In all placebo-controlled trials conducted by Amgen,
injection site reactions (ISRs) were frequently reported in
the majority of patients (95% of which were reported to
be mild to moderate in severity). ISRs included erythema,
ecchymosis, inflammation and pain. On a dose of 100
mg/day, 71% of patients developed an ISR (n = 1565)
compared to 28% of placebo treated patients (n = 733).
The median duration of typical symptoms was 14 to 28
days. Other adverse events reported by patients adminis-
tered with IL-1ra were, URI, headache, nausea, diarrhoea,
sinusitis, arthralgia, flu like symptoms and abdominal
pain. Allergic reactions reported in patients were rare.
Reported ISRs and other drug related adverse reactions
will be reported on the adverse event report in the CRF.
Patients reporting ISRs will be required to identify another
injection site in which to administer the injection. Inves-
tigators will submit all adverse events reports for each
patient to the CTEU at days 7, 14 and 30, three months
and one year. The CTEU will maintain a log of all adverse
reactions.
Serious adverse events/reactions
Serious adverse events (SAE) or reactions can be defined
as any untoward medical occurrence or effect that at any
dose
• results in death,
• is life-threatening,
• requires hospitalisation or prolongation of existing
inpatients hospitalisation,
• results in persistent or significant disability or incapac-
ity,
• is a congenital anomaly or birth defect.
Expected serious adverse events/clinical outcomes due to underlying 
acute coronary syndrome
• Myocardial Infarction (MI)
• Stroke
• Revascularisation
• Major Bleed
• DeathPage 9 of 14
(page number not for citation purposes)
Trials 2008, 9:8 http://www.trialsjournal.com/content/9/1/8Drug related serious adverse reactions
• Serious Infections – Previous trials conducted by Amgen
demonstrated an incidence of serious infections in 1.8%
of IL-1ra treated patients compared to 0.7% in placebo
group. There were no on-study deaths due to serious infec-
tious episodes.
• Neutropenia – Administration of IL-1ra was associated
with neutropenia (ANC < 1.5 × 109/I) in 2.4% of patients
compared with 0.4% of placebo patients. None of these
patients had serious infections associated with the neutro-
penia.
Reporting of serious adverse events/reactions
The CRF will contain specific SAE reports relating to the
SAEs/clinical outcomes listed above. The investigator will
complete the SAE report in the CRF, including date of
event, admissions, diagnosis details, date of discharge or
death. Those SAEs considered a suspected unexpected
serious adverse reaction (SUSAR) will be marked "possi-
ble SUSAR" on the SAE report. The investigator will also
attach a discharge/medical summary and fax to the CTEU
with the SAE report within 24 hours. Any other SAE not
fitting the criteria above will be reported on the "other
SAE" report in the CRF.
The CTEU will review all serious adverse event/reaction
reports before sending an electronic copy to the SAEC for
adjudication. All reported SAE/Rs will be adjudicated by
the SAEC to assess the seriousness and causality between
the IMP and/or concomitant therapy and serious adverse
event/reaction. This assessment must take place within
two working days upon receipt of the electronic copy of
the form. If the SAEC judge the SAE/R to constitute a
SUSAR, the CTEU will ensure expedited reporting proce-
dures are followed.
Suspected unexpected serious adverse reactions (SUSARS)
A SAR can be considered unexpected when the adverse
reaction, the nature or severity of which is not consistent
with the applicable product information. All suspected
unexpected serious adverse reactions related to an IMP,
which occur during the trial, are subject to expedited
reporting.
Reporting of SUSARs
The CTEU will unblind the SUSAR report before sending
it electronically to the SAEC with the medical summary
attached. The SAEC will review the report and summary
within two working days and adjudicate whether the
event constitutes a SUSAR. The SAEC will inform the
CTEU of their decision to ensure expedited reporting pro-
cedures are followed if necessary.
Expedited reporting of SUSARs
All SUSARs will be reported to the MHRA and NHS REC,
by the trial co-ordinating site (CTEU). All SUSAR reports
will be unblinded by the CTEU prior to submission. A
SUSAR, which is fatal, or life threatening will be reported
to the MHRA and the main REC by the CTEU as soon as
possible and within 7 days after the CTEU become aware
of the event. A SUSAR, which is not fatal, or life threaten-
ing must be reported to the MHRA and main Research
Ethics Committee (REC) as soon as possible and within15
days after the CTEU become aware of the event. The CTEU
will inform all trial investigators of all reported SUSARs
within 15 working days.
Annual reporting
The CTEU will submit annual safety reports of all sus-
pected serious adverse reactions in accordance with regu-
latory requirements to the MHRA and Main REC. Annual
safety reports will be submitted to the MHRA on the date
of the original clinical trials authorisation. Annual
progress reports will also be submitted to the main REC
on the same date. Annual safety reports will also be sub-
mitted to the Data Monitoring Committee for review.
Participant withdrawal
Investigators must ascertain the reasons for the with-
drawal due to adverse events, failure to attend, non-com-
pliance, withdrawal of consent or other reasons. The
withdrawal form must be faxed to the CTEU within five
working days, unless withdrawal is due to a SAE, in which
case the investigator will follow SAE reporting procedures.
Unblinding
The treatment code must not be broken except in medical
emergencies when the appropriate management of the
patient necessitates knowledge of the treatment. Each
pharmacy will keep a copy of the randomisation alloca-
tion list, in case unblinding is necessary. Should a SUSAR
occur, the CTEU will unblind the patient and follow expe-
dited reporting procedures.
Indemnity
Patients that are enrolled into the study are covered by
indemnity for negligent harm through the standard NHS
Indemnity arrangements. The University of Sheffield has
insurance to cover for non-negligent harm associated with
the protocol. IL1-ra is commercially available for the treat-
ment of inflammatory arthritic conditions. The rate of
serious side effects attributable to treatment is <1%. This
will include cover for additional health care, compensa-
tion or damages whether awarded voluntarily by the
Sponsor, or by claims pursued through the courts. Inci-
dences judged to arise from negligence (including those
due to major protocol violations) will not be covered by
study insurance policies. The liability of the manufacturerPage 10 of 14
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claims arising from faulty manufacturing of the commer-
cial product and not to any aspects of the conduct of the
study.
Ethics
This study will conform with the Declaration of Helsinki
guidelines on research involving human subjects. The
study protocol will be submitted to the Multi-centre
Research Ethics Review Committee, and Ethics Commit-
tees at each centre participating in the study and approval
obtained before the study commences.
Publication policy and dissemination of results
The results from the trial will be submitted for publication
in a major journal irrespective of the outcome. The Trial
Steering Committee will be responsible for approval of all
manuscripts arising from the study prior to submission
for publication. Sub-studies of centre-specific data may
only be carried out with the knowledge and approval of
the Trial Steering Committee.
Any individual authorship of presentations and reports
related to the study will be on behalf of the collaborative
group. The final follow-up study results paper will name
local co-ordinators as well as those involved in central co-
ordination and trial management.
At the end of the study, patients will be able to request a
copy of the results of the study from the investigator at
that site.
Proposed study timetable
March 2006 – Grant awarded by MRC
Jan 2007 – Recruitment starts
Dec 2009 – Recruitment completed
Jan 2010 – Last patient completes 30 day follow up
2010 – Publication of data
Abbreviations
CRP – C Reactive Protein. IL-1 – Interleukin 1. IL-1ra –
Interleukin 1 receptor antagonist. ACS – Acute Coronary
Syndrome. ECG – Electrocardiogram. AUC – Area under
the curve. REC – Research Ethics Committee. IMP – Inves-
tigational Medicinal Product.
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Appendices
Appendix 1 – Pharmacy locations
Sheffield Teaching Hospitals NHS Trust
Dr David Smith
Pharmacy Information Services Manager
Northern General Hospital
Herries Road
Sheffield
S5 7AU
Edinburgh Royal Infirmary
Prof Norman Lannigan
Head of Pharmacy
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh
EH16 4SA
Leeds General Infirmary
Dr Caroline BedfordPage 11 of 14
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Leeds Teaching Hospitals NHS Trust
Leeds
Labelling
Examples of the labelling can be found appended to the
Summary of Product Characteristics.
Storage
Store in a refrigerator (2°C – 8°C).
Manufacturer's authorisation
EU/1/02/203/001-003
Transportation of samples to core lab
Samples will be stored in -20°C freezers at each centre. All
participating centres have research freezers available for
use. FedEx will then send samples in batches to the core
labs.
Appendix 2 – Sub study protocols
1. Cardiac Magnetic Resonance imaging sub study
The Leeds cohort of patients will undergo baseline and
follow-up Gadolinium enhanced CMR as a quantitative
measurement of extent of myocardial injury. We wish to
evaluate the possible mechanisms of any potential benefit
and, therefore, feel that investigation of myocardial func-
tion, infarct size and oedema is justified. CMR is an accu-
rate and reproducible technique for making these
assessments. CMR can distinguish between scar tissue
(following myocardial infarction/acute coronary syn-
dromes) and normal (viable) myocardium using the late
gadolinium hyper-enhancement technique [38,39]. CMR
can also differentiate acute from chronic infarction, based
on the principle that acute infarctions are surrounded by
tissue oedema secondary to the inflammatory process
[40]. Thus, CMR is well suited to extend our understand-
ing of the mechanism of any potential benefit from IL-1ra
treatment at the time of NSTEMI ACS. Therefore, we plan
a CMR sub-study in the Leeds patients who will have a
CMR scan within 48 h of presentation using the protocol
outlined below. A follow-up scan, using the same proto-
col, will be performed after the completion of randomised
therapy. Quantification of myocardial oedema, myocar-
dial scar and ventricular volumes/function will be per-
formed on both scans. Exploratory statistical analysis will
be undertaken for serial change in these measures within
patients and between groups.
CMR imaging procedure
1) Localisers and breath-hold plan scans to define LV
short axis. 2) Resting wall-motion sequence. Multiphase
HLA, VLA and short axis cine stack (10–12 slices) using a
fast gradient echo sequence to assess wall motion. Then in
identical scan planes; Breath hold, black blood, T2-
weighted triple inversion recovery sequence. 3) Late gado-
linium hyper-enhancement CMR: T1-weighted, seg-
mented inversion-recovery sequence 15 minutes after
intravenous injection of Gadolinium (0.2 mmol/kg). This
protocol will be piloted on 20 patients before the start of
the main clinical trial.
2. ST-Holter segment analysis sub study
As soon as possible after recruitment, between days 2 and
4 of treatment, Sheffield patients will be identified as suit-
able for ST segment monitoring. Exclusion criteria will
include bundle branch block, significant conduction
abnormality, digoxin therapy or serious electrolyte distur-
bance. The presence of other potentially confounding fea-
tures, such as mitral valve prolapse, posture change,
changes due to body habitus and temperature change will
be assumed to be similar in the two groups. A Holter mon-
itor will be attached using the 3 standard leads for 24 h. If
catheterisation be performed during the period of the
recording, an appropriate entry will be made on the time
log prior to the monitor being removed and replaced
afterwards. If revascularisation be undertaken, the moni-
tor will not be replaced. The monitor will be removed by
one of the ECG technicians after 24 h (or as just stated)
and analysed by Ms Gomersall (an experienced ECG tech-
nician who works in Sheffield), using the standard Rey-
nolds protocol for ST segment analysis. She will be
blinded to the identity of the treatment. The number of
ischemic events, their frequency and total duration will be
compared in both treatment groups.
3. Forearm endothelial cell response sub study
This study will examine the effect of Interleukin-1 receptor
antagonist (IL-1ra) on vasomotor and fibrinolytic func-
tion in the forearm circulation of patients with acute cor-
onary syndromes. The pro-inflammatory cytokines
Interleukin-1 (IL-1) and tumour necrosis alpha-α (TNF-α)
have been implicated in the initiation and amplification
of local and systemic inflammatory responses leading to
the development of, and progression of atherosclerosis.
However the direct in vivo effects of cytokines in patients
with IHD on endothelial vasomotor and fibrinolytic func-
tion are unknown. As acute coronary syndromes are asso-
ciated with both impaired fibrinolytic function and
transient elevation of acute phase proteins we wish to
establish whether IL-1ra affects endothelial function.
Patients will be recruited for the main study. Those
recruited in Edinburgh (n = 62) will be asked if they are
also prepared to participate in this sub-study. Recruited
subjects will attend on two occasions. A comparison of IL-
1ra versus placebo on endothelial function will be under-
taken. The first study will be performed on days 2–4 fol-Page 12 of 14
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administration of either IL-1ra or placebo (typically 1–4
h). The second study will be performed on day 14 at the
same time of day as the first study. Volunteers will have
fasted and avoided caffeine for at least four hours and
avoided alcohol for 24 hours prior to each study. The sub-
jects will undergo brachial artery cannulation with a 27
standard wire gauge under controlled conditions. Fore-
arm blood flow will be measured in the infused and non-
infused arms by venous occlusion plethysmography using
mercury-in-silastic strain gauges. Blood samples will be
obtained from 17-gauge venous cannulae inserted into
the antecubital fossae of both forearms.
Selective infusions into the brachial artery of the non-
dominant arm will be undertaken. Substance P will be
infused at 2, 4, 8 pmol/min, acetylcholine at 5, 10 and 20
μg/min (endothelium-dependent vasodilator that does
not release t-PA), and sodium nitroprusside at 2, 4 and 8
μg/min (endothelium-independent vasodilator that does
not release t-PA) will be infused for 5 min at each dose.
Blood samples will be taken simultaneously from each
forearm at baseline, immediately following, and at 4 fur-
ther time points after the TNF-α infusion (total less than
200 mls on each occasion). These time points have been
derived using the results of previous work to minimise
non-contributory venous samples. Blood will be taken to
assess stimulated coagulation factors and cytokines. Sam-
ples for plasma cotinine, haematocrit, white cell count
will also be taken.
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